NCT02579382 - Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

January 16, 2017

Study Completion Date

May 3, 2019

Conditions

Chronic Hepatitis B

Interventions

DRUG

TDF

300 mg tablets administered orally once daily

DRUG

Vesatolimod

Tablets administered orally once a week (every 7 days) for 12 doses

DRUG

Placebo

Placebo administered orally once a week (every 7 days) for 12 doses

Trial Locations (21)

Los Angeles

Palo Alto

San Diego

San Francisco

Honolulu

Catonsville

Boston

Flushing

Philadelphia

Toronto

Kowloon

Bologna

Milan

Pisa

San Giovanni Rotondo

Grafton

Daegu

Seoul

Dalin

Kaohsiung City

London